SCHEMBL23250778

SCHEMBL23250778

O=c1cccc(C2CC3CCC(C2)O3)cc1O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ OPRM1 P35372 6/20 0.33
▸ OPRD1 P41143 6/20 0.33
▸ DBH P09172 2/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ KMO O15229 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ QDPR P09417 3/20 0.33
▸ NOTUM Q6P988 1/20 0.32
▸ ALOX5 P09917 1/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ MGLL Q99685 1/20 0.31
▸ ALOX15B O15296 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23250721 0.80 HDAC4 (0.49) HDAC4HDAC2HDAC8OPRM1OPRD1
SCHEMBL23250681 0.79 ESR2 (0.37) HDAC4HDAC2HDAC8DBHMMP2
SCHEMBL21471548 0.78 HDAC4 (0.74) HDAC4HDAC2HDAC8DBHMMP2
SCHEMBL23258680 0.78 HDAC4 (0.54) HDAC4HDAC2HDAC8DBHMMP2
SCHEMBL21471547 0.77 HDAC4 (0.72) HDAC4HDAC2HDAC8OPRM1OPRD1
SCHEMBL23258566 0.74 QDPR (0.62) HDAC4HDAC2HDAC8KMOQDPR
SCHEMBL23250752 0.73 HDAC4 (0.53) HDAC4HDAC2HDAC8DBHMMP2
SCHEMBL23433185 0.73 HDAC4 (0.53) HDAC4HDAC2HDAC8KMOMGLL
SCHEMBL23258498 0.72 SLC6A4 (0.35) HDAC4HDAC2HDAC8OPRM1OPRD1
SCHEMBL27304483 0.72 HDAC4 (0.39) HDAC4HDAC2HDAC8QDPRALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Kinesid Therapeutics, Inc (US) 2023-12-21 — — US disclosed
EP-4045477-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 — — EP disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TFRC, SDHB HDAC4 2346/4885HDAC2 2245/4885HDAC8 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback